D. Apt

发表

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.

R. Laing, S. Chan, L. Fehrenbacher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

NFI-B3, a Novel Transcriptional Repressor of the Nuclear Factor I Family, Is Generated by Alternative RNA Processing*

H. Bernard, Yichun Liu, D. Apt, 1997, The Journal of Biological Chemistry.

Nuclear factor I and epithelial cell-specific transcription of human papillomavirus type 16

H. Bernard, Y. Liu, D. Apt, 1993, Journal of virology.

Endogenous retroviral env genes after N-methyl-N'-nitro-N-nitrosoguanidine treatment of mouse tumor cells: stable DNA amplification and rearrangement.

P. Altevogt, D. Apt, J. Schreck, 1989, Cancer research.

Transcriptional control and cell type specificity of HPV gene expression.

H. Bernard, D. Apt, 1994, Archives of dermatology.

The enhancer of human papillomavirus type 16: binding sites for the ubiquitous transcription factors oct-1, NFA, TEF-2, NF1, and AP-1 participate in epithelial cell-specific transcription

B. Gloss, H. Bernard, M. Isa, 1991, Journal of virology.

High-frequency generation of altered Mr 70,000 env glycoproteins in N-methyl-N'-nitro-N-nitrosoguanidine-treated murine tumor cells.

P. Altevogt, D. Apt, 1988, Cancer research.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

M. Zauderer, R. Yeh, J. Ware, 2016, Clinical Cancer Research.

High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transformation correlate with the activation of the HPV-16 promoter.

H. Bernard, G. Suske, D. Apt, 1996, Virology.

Overcoming antigenic diversity and improving vaccines using DNA shuffling and screening technologies

V. Heinrichs, R. Whalen, C. Locher, 2004, Expert opinion on biological therapy.

Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony‐stimulating factor derivative Maxy‐G34 and pegfilgrastim in rats

M. Scholz, M. Loeffler, C. Engel, 2009, Cell proliferation.

1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC)

R. Laing, L. Fehrenbacher, R. Roylance, 2015 .

EpCAM-specific Vaccine Response by Modified Antigen and Chimeric Costimulatory Molecule in Cynomolgus Monkeys

J. Punnonen, S. Leong, M. Neighbors, 2008, Journal of immunotherapy.

Diverse plasmid DNA vectors by directed molecular evolution of cytomegalovirus promoters.

W. Stemmer, A. Crameri, J. Punnonen, 2005, Human gene therapy.

A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.

K. Porter, J. Punnonen, Shuenn-Jue Wu, 2006, Virology.

Abstract P5-19-10: Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2015 .

Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.

K. Porter, J. Punnonen, K. Raviprakash, 2006, Vaccine.

Cloning and functional analysis of spliced isoforms of human nuclear factor I-X: interference with transcriptional activation by NFI/CTF in a cell-type specific manner.

H. Bernard, Y. Liu, D. Apt, 1994, Nucleic acids research.